Chemical structure of PKC412.
Western blot analysis of extracts from Jurkat cells, untreated or treated with Calyculin A #9902 (50 nM, 20 min) with or without pre-treatment with PKC412 (24 hr) for the indicated concentrations, using Phospho-(Ser) PKC Substrate Antibody #2261 (upper) and β-Actin (13E5) Rabbit mAb #4970 (lower).
Western blot analysis of extracts from SEM cells, untreated (-) or treated with PKC412 (1 μM, 24 hr; +), using Phospho-FLT3 (Tyr589/591) (30D4) Rabbit mAb #3464 (upper) and FLT3 (8F2) Rabbit mAb #3462 (lower).
PKC412 is supplied as a lyophilized powder. For a 10 mM stock, reconstitute 1 mg in 175.24 μL DMSO. Working concentrations and length of treatment can vary depending on the desired effect, but it is typically used at 0.1-10 μM for 18-48 hours. Soluble in DMSO at 100 mg/mL; soluble in ethanol at 5 mg/mL with warming; very poorly soluble in water with maximum solubility estimated to be about 10-20 μM.
Store lyophilized or in solution at -20ºC, desiccated. Protect from light. In lyophilized form, the chemical is stable for 24 months. Once in solution, use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.
|Molecular Weight||570.64 g/mol|
|Solubility||Soluble in DMSO at 100mg/ml and EtOH at 5mg/ml.|
The staurosporine analog, PKC412, inhibits a variety of serine/threonine and tyrosine kinases including PKC (IC50 = 50 nM), cyclic AMP-dependent protein kinase (IC50 = 2.4 µM), S6 kinase (IC50 = 5.0 µM), and EGFR (epidermal growth factor receptor) tyrosine kinase activity (IC50 = 3.0 µM) (1). PKC412 has also demonstrated stong inhibitory effects on FLT3, which causes G1 cell cycle arrest and apoptosis (2).
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST's products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST's Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.